Summary: Long-acting β2-agonists (LABA), long-acting muscarinic antagonists (LAMA) and inhaled corticosteroids (ICS) are the main therapeutics in bronchial asthma and COPD. There are many combinations of them, including all three in the most severe cases. This is called triple therapy. Single-inhaler triple therapy seems to be its best form as regards adherence. The paper discusses current indications in bronchial asthma as well as COPD, and briefly describes several developed drugs. The authors take a closer look at completed clinical trials and the legislative process.